The latest report Cellular Tumor Antigen p53 - Pipeline Review, H2 2017, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects.
Report Source: www.themarketreports.com/report/ce…e-review-h2-2017
- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53
- The report reviews Cellular Tumor Antigen p53 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
Report available at: www.themarketreports.com/report/buy-now/941400
- Aprea AB
- CanBas Co Ltd
- Critical Outcome Technologies Inc
- Innovation Pharmaceuticals Inc
- ORCA Therapeutics BV
- OSE Immunotherapeutics
- Quark Pharmaceuticals Inc
Got a question; ask us at: www.themarketreports.com/report/ask-your-query/941400
Category: Market Research Publishers and RetailersCompany about: The Market Reports aims to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are dealing with so many Publishers, we can actually give you what suits best in accordance to your requirements.
For more information: